Skip Page Header

Home > Interventions for smoking cessation and reduction in individuals with schizophrenia.

Tsoi, Daniel T and Porwal, Mamta and Webster, Angela C (2013) Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database of Systematic Reviews , (2) . Art. No.: CD007253. DOI: 10.1002/14651858.CD007253.pub3.

URL: https://www.cochranelibrary.com/cdsr/doi/10.1002/1...


Are there any effective interventions to help individuals with schizophrenia to quit or to reduce smoking?

 

People with schizophrenia are very often heavy smokers. It is uncertain whether treatments that have been shown to help other groups of people to quit smoking are also effective for people with schizophrenia. In this review, we analysed studies which investigated a wide variety of interventions. Our results suggested that bupropion (an antidepressant medication previously shown to be effective for smoking cessation) helps patients with schizophrenia to quit smoking. The effect was clear at the end of the treatment and it may also be maintained after six months. Patients who used bupropion in the trials did not experience any major adverse effect and their mental state was stable during the treatment.

 

Another medication, varenicline (a nicotine partial agonist which has been shown to be an effective intervention for smoking cessation in smokers without schizophrenia), also helps individuals with schizophrenia to quit smoking at the end of the treatment. However, this evidence is only based on two studies. We did not have sufficient direct evidence to know whether the benefit of varenicline is maintained for six months or more. In addition, there has been ongoing concern of potential psychiatric adverse events including suicidal ideas and behaviour among smokers who use varenicline. We found that two patients, among 144 who used varenicline, had either suicidal ideas or behaviour. Smokers with schizophrenia who receive money as a reward for quitting may have a higher rate of stopping smoking whilst they get payments. However, there is no evidence that they will remain abstinent after the reward stops. There was too little evidence to show whether other treatments like nicotine replacement therapy and psychosocial interventions are helpful.

Item Type
Article
Publication Type
Review
Drug Type
Tobacco / Nicotine
Intervention Type
Harm reduction, Rehabilitation/Recovery
Date
February 2013
Identification #
Art. No.: CD007253. DOI: 10.1002/14651858.CD007253.pub3
Publisher
John Wiley & Sons, Ltd
Place of Publication
London
Number
2
EndNote
Accession Number
HRB (Not in collection)

Repository Staff Only: item control page